CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 1.61: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.51BCNY374.93M · vs all stocks (USD)
Revenue (TTM)
486.70MCNY72.60M · vs all stocks (USD)
Profit Margin
-53.31%Beta
0.1910xvs all stocks
52-Week Change
3.60%vs all stocks
Market Capitalization
2.51BCNY374.93M · vs all stocks (USD)
Enterprise Value
2.71BCNY404.91M · vs all stocks (USD)
Price to Sales (TTM)
5.16xPrice to Book (MRQ)
3.48xEnterprise to Revenue
5.58xEnterprise to EBITDA
-170.07xGross Margin
44.10%Profit Margin
-53.31%Operating Margin
6.59%Return on Assets (TTM)
-2.18%Return on Equity (TTM)
-33.42%Revenue (TTM)
486.70MCNY72.60M · vs all stocks (USD)
Revenue per Share (TTM)
0.7750CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-25.00%Gross Profit (TTM)
210.69MCNY31.43M · vs all stocks (USD)
EBITDA (TTM)
-15.96MCNY-2.38M · vs all stocks (USD)
Net Income (TTM)
-259.47MCNY-38.70M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-2.60%Operating Cash Flow (TTM)
85.92MCNY12.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-119.40MCNY-17.81M · vs all stocks (USD)
5-Year Average Dividend Yield
0.22%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-8.86MCNYFY2025 · Dec 31, 2025Revenue
545.50MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
285.78MCNYFY2025 · Dec 31, 2025Gross Profit
259.71MCNYFY2025 · Dec 31, 2025Operating Income
-93.21MCNY-13.90M · vs all stocks (USD)
Pre-tax Income
-337.03MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.05MCNYFY2025 · Dec 31, 2025Net Income
-346.08MCNYFY2025 · Dec 31, 2025EBIT
-326.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-79.92MCNYFY2025 · Dec 31, 2025Research & Development
23.44MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
234.56MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.27MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
10.99MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5100CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
628.27MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
628.27MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-346.08MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
25.66MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-84.88MCNYFY2025 · Dec 31, 2025Free Cash Flow
-147.14MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
96.69MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-346.08MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.14MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
203.79MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
36.28MCNYFY2025 · Dec 31, 2025Capital Expenditures
-62.26MCNYFY2025 · Dec 31, 2025Net Acquisitions
920.67KCNYFY2025 · Dec 31, 2025Sale of Investments
201.97MCNYFY2025 · Dec 31, 2025Other Investing Activity
14.24MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
154.88MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
190.45MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-430.97MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-13.30MCNYFY2025 · Dec 31, 2025Other Financing Charges
-7.99MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-261.81MCNYFY2025 · Dec 31, 2025Shares Outstanding
623.72MSharesUpdated Sep 19, 2026Float Shares
510.81MSharesUpdated Sep 19, 2026% Held by Insiders
29.88%vs all stocks
% Held by Institutions
1.34%vs all stocks
Total Cash (MRQ)
119.88MCNY17.88M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1920CNYUpdated Sep 19, 2026Total Debt (MRQ)
402.09MCNY59.98M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5667xCurrent Ratio (MRQ)
0.7970xBook Value per Share (MRQ)
1.16CNYUpdated Sep 19, 2026Total Assets
1.39BCNY207.21M · vs all stocks (USD)
Total Current Assets
459.62MCNYFY2025 · Dec 31, 2025Total Liabilities
682.29MCNYFY2025 · Dec 31, 2025Total Non-current Assets
929.54MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
89.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
592.46MCNYFY2025 · Dec 31, 2025Cash
101.01MCNYFY2025 · Dec 31, 2025Cash Equivalents
22.27MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
123.28MCNYFY2025 · Dec 31, 2025Accounts Receivable
229.82MCNYFY2025 · Dec 31, 2025Inventory
55.76MCNYFY2025 · Dec 31, 2025Accounts Payable
145.22MCNYFY2025 · Dec 31, 2025Short-term Debt
312.44MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.27MCNYFY2025 · Dec 31, 2025Long-term Debt
50.85MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
4.79MCNYFY2025 · Dec 31, 2025Common Stock (Book)
623.72MCNYFY2025 · Dec 31, 2025Retained Earnings
-105.73MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
706.87MCNY105.44M · vs all stocks (USD)
52-Week Low
3.40CNYUpdated Sep 19, 202652-Week High
4.79CNYUpdated Sep 19, 202652-Week Change
3.60%vs all stocks
Beta
0.1910xvs all stocks
50-Day MA
3.95CNYUpdated Sep 19, 2026200-Day MA
4.00CNYUpdated Sep 19, 2026Avg 10-Day Volume
12.84MSharesUpdated Sep 19, 2026Avg 30-Day Volume
15.63MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.4100CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.44Profit Margin: -0.53
Financial Health
Altman Z-Score 1.61: grey zoneSignificant
Altman Z-Score: 1.61
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule